Heart-Type Fatty Acid-Binding Protein (H-FABP) and its Role as a Biomarker in Heart Failure: What Do We Know So Far?

Abstract

BACKGROUND:

Heart failure (HF) remains one of the leading causes of death to date despite extensive research funding. Various studies are conducted every year in an attempt to improve diagnostic accuracy and therapy monitoring. The small cytoplasmic heart-type fatty acid-binding protein (H-FABP) has been studied in a variety of disease entities. Here, we provide a review of the available literature on H-FABP and its possible applications in HF. Methods: Literature research using PubMed Central was conducted. To select possible studies for inclusion, the authors screened all available studies by title and, if suitable, by abstract. Relevant manuscripts were read in full text.

RESULTS:

In total, 23 studies regarding H-FABP in HF were included in this review.

CONCLUSION:

While, algorithms already exist in the area of risk stratification for acute pulmonary embolism, there is still no consensus for the routine use of H-FABP in daily clinical practice in HF. At present, the strongest evidence exists for risk evaluation of adverse cardiac events. Other future applications of H-FABP may include early detection of ischemia, worsening of renal failure, and long-term treatment planning.

• Authors: Richard Rezar, Peter Jirak, Martha Gschwandtner, Rupert Derler, Thomas K Felder, Michael Haslinger, Kristen Kopp, Clemens Seelmaier, Christina Granitz, Uta C Hoppe, Michael Lichtenauer
• Journal: Journal of clinical medicine (J Clin Med) Vol. 9 Issue 1 (Jan 07 2020) ISSN: 2077-0383 [Print] Switzerland
• PMID: 31936148 (Publication Type: Journal Article, Review)